Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Abbott Medical - VERITAS Study

NCT06707688 · View on ClinicalTrials.gov ↗

Study Summary

The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation.

Interventions

  • DEVICE Amulet™ 2 Left Atrial Appendage (LAA) Occluder

Study Locations (20)

Texas

  • Texas Cardiac Arrhythmia — Austin
  • Baylor Scott & White All Saints Medical Center — Fort Worth
  • Vital Heart and Vein — Humble
  • Baylor Scott & White - The Heart Hospital Plano — Plano
  • Heart Rhythm Associates — Shenandoah

Florida

  • Baptist Medical Center — Jacksonville
  • AdventHealth Orlando — Orlando

New York

  • NYU Langone Health — New York
  • Mount Sinai Hospital — New York

South Carolina

  • Roper Hospital — Charleston
  • Trident Medical Center — Charleston

Arizona

  • Arizona Arrhythmia Research Group — Phoenix

Arkansas

  • Arrhythmia Research Group — Jonesboro

Georgia

  • Northside Hospital — Atlanta

Kansas

  • Kansas City Cardiac Arrhythmia Research Foundation — Overland Park

Trial Details

FieldValue
Enrollment Target 458 participants
Start Date 2024-11-07
Est. Completion 2027-09
Phase NA

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06707688

The ClinicalTrials.gov registry entry for NCT06707688 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 1 intervention — of which Amulet™ 2 Left Atrial Appendage (LAA) Occluder is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06707688 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Texas, Florida, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06707688 about?

NCT06707688 is a clinical study titled "Abbott Medical - VERITAS Study". The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriat...

What is the current status of trial NCT06707688?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 458 participants. The study started on 2024-11-07. Estimated completion is 2027-09.

What conditions does trial NCT06707688 study?

This clinical trial studies the following conditions: Atrial Fibrillation (AF), Stoke. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06707688?

The interventions under investigation include: Amulet™ 2 Left Atrial Appendage (LAA) Occluder (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06707688?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06707688 being conducted?

This trial has 20 study locations across Arizona, Arkansas, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial